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regimen for patients. Prevention and/or reduction of mucositis
should start with the development of a standardized oral care
regimen that will be used consistently in the clinical management
of the patient. Mouth care protocols should also be simple and easy
to perform in order to ensure that patients will be compliant with
an oral care regimen. The goal is to determine the most effective
treatment available to prevent mucositis, treat the signs and symp-
toms of mucositis, and provide information to be used to develop
a new oral care standard for patients in the BMT unit at UAB.
Currently, all patients receiving a BMT at UAB regardless of their
diagnosis or chemotherapy regimen are placed on the same mouth
care protocol, which is to be used every four hours. This protocol
includes biotine, chlorhexadine, sucralfate, and nystatin. According
to the nurses in the BMT unit, patients do not consistently use the
mouth care provided. Patients complain that there are too many
steps involved, report an unpleasant taste, nausea, and anxiety
when it is time to do mouth care. During 2004, 12 out of 77
patients at UAB had grade 3 mucositis and 42 out of 77 had grade
2 mucositis. Recommendations were made for high- risk patients
(identiﬁed prior to receiving chemotherapy) to receive an aggres-
sive oral care protocol, including the use of palifermin. All low-risk
patients would receive saline rinses, or salt water and baking soda
solutions in order to prevent or treat mucositis.
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VENO OCCULSIVE DISEASE: A POTENTIALLY LIFE THREATENING COM-
PLICATION OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
Summers, E., Edmisten, J., Martin, P.L., Frey, M., Kurtzberg, J.
Pediatric Blood and Marrow Transplant Program at Duke University
Medical Center, Durham, NC.
Veno Occlusive disease (VOD) is a potentially life threatening
liver complication occurring in up to 5% of patients undergoing
hematopoietic stem cell transplantation (HSCT). It usually occurs
before day 35 post transplant and presents with signs and symp-
toms including painful hepatomegaly, jaundice, ﬂuid retention,
weight gain of 	5%, and ascites. Patients with VOD consume
platelets, are often refractory to platelet transfusions and become
coagulopathic. VOD occurs when the blood vessels of the liver
become swollen and congested, diminishing the liver’s ability to
remove toxins and waste from the blood. Fluids may build up in the
liver causing additional swelling and tenderness (Mullaly K., 2002).
Duke Low dose heparin infused continuously for the ﬁrst 28 days
post transplant  actigall can be used as prophylaxis against VOD.
Patients at high risk for VOD may be identiﬁed during the trans-
plant workup and include those with prior liver disease, iron
overload, decreased protein C, and heavily pretreated patients with
malignancies. An attempt is made to avoid the use of hepatotoxic
agents, but radiation, cytoxan, and busulfan are frequently neces-
sary to treat the patient’s underlying disease. The use of deﬁb-
rotide, an investigational agent with local thrombolytic activity,
appears to be a safe and effective treatment options for patients
with VOD. Studies have reported up to 50% of children respond-
ing favorably to treatment with deﬁbrotide when signiﬁcant VOD
has occurred. Nurses play an important role in diagnosing VOD in
pediatric patients by ﬁrst monitoring strict IOs, daily weights, and
pain reported by the patients on assessment. The purpose of this
poster is to: (1) describe the signs and symptoms of Veno Occlusive
disease; (2) state the treatment modalities currently used for treat-
ment and prevention of VOD; and (3) describe important aspects
of nursing care of the pediatric patient with VOD.
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THE DEVELOPMENT OF AN ALGORITHM MANAGING ACUTE DELIRIUM
IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
(SCT)
Shelburne, N.F., Simpson, K.K., Bevans, M.F. National Institutes of
Health, Clinical Center, Bethesda, MD.
Delirium is deﬁned as an acute and ﬂuctuating disruption of
attention and cognition that is not accounted for by preexisting
dementia. Fann et al (2002) reports that up to 50% of recipients
undergoing a SCT experience delirium. Pretreatment predictors of
delirium have been identiﬁed in oncology patients, which are
frequently present in SCT recipients, in addition to the direct and
indirect effects of their intense treatment. Negative outcomes as-
sociated with delirious behavior can include increased length of
stay, and injuries related to falls or other self inﬂicted behaviors.
Current literature focuses on the identiﬁcation of predictors and
reliable recognition of delirium. Minimal information is available
to guide the use of interventions to avoid negative consequences.
The purpose of this project was to develop a standardized approach
to improve the recognition of delirium, identify SCT patients at
high risk for delirium, and guide nursing interventions to decrease
complications.
The Delirium Intervention Algorithm was activated with 15
SCT inpatients during a 3-month time period, including 5 (33%)
myeloablative, and 10 (66%) nonmyeloablative. Three (20%) pa-
tients experienced acute delirium, and 9 (75%) were identiﬁed at
high risk for delirium. One (11%) high risk patient experienced a
fall. High risk patients experienced elevations in kidney and liver
function, narcotic and benzodiazepine use, and alterations in
mood/affect. The application of the Delirium Intervention Algo-
rithm improved the care of SCT patients by guiding nurses in the
early recognition of delirium, the identiﬁcation and removal of
contributing factors, and the use of interventions to ensure patient
safety and maintain dignity. Implementation of this standardized
approach to patient care empowers the nurse to effectively reduce
length of stay and morbidity in SCT recipients at risk for compli-
cations from delirium.
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STRONGYLOIDES STERCORALIS IN THE IMMUNOCOMPROMISED POP-
ULATION
Rivera, Z.R., Massaro, A. University of Texas M. D. Anderson Cancer
Center, Houston, TX.
Blood Marrow Transplant (BMT) patients are typically immu-
nocompromised for prolonged periods. Due to a compromised
immune system, BMT patients are susceptible to acquiring oppor-
tunistic infections. Infectious organisms may include parasites such
as Toxoplasma gondii, Pneumocystis carinii, Entamoeba coli, and more
infrequently Strongyloides stercoralis.
Strongyloides stercoralis is an intestinal nematode of humans esti-
mated affecting tens of millions of persons worldwide. This para-
site is endemic in tropical or temperate and subtropical climates.
Risk factors may include travel to those areas. S. stercoralis can
transform into a fulminant fatal illness in certain conditions asso-
ciated with a compromised host. With the increased mortality and
morbidity associated with S. stercoralis focusing on identifying,
screening, and treating those at risk is warranted. Of the individ-
uals who are infected with S. stercoralis, 50% are asymptomatic and
75% manifest eosinophilia. Clinical symptoms include epigastric
pain and tenderness, diarrhea, nausea and vomiting, constipation,
and weight loss. In BMT patients, there may be an acceleration of
the autoinfection cycle which can result in hyperinfection syn-
drome and/or disseminated strongyloidiasis increasing the high
probability of multi-organ system invasion. Treatment goals of
patients with S. stercoralis are directed toward preventing hyperin-
fection and dissemination, as well as complete eradication. Three
oral preparations are available for use in uncomplicated intestinal
strongyloidiasis, these include: thiabendazole, albendazole, and
ivermectin. Multi-dose scheduled regimens may be necessary. Ed-
ucational opportunities should focus on increasing clinician’s
knowledge about clinical manifestations, diagnosis/pathogenesis,
and treatment of this infrequent infection to facilitate earlier rec-
ognition of and/or surveillance for infection in high-risk patients.
A case study of a BMT patient will be presented.
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PATIENT ACCESS: ENHANCING THE REFERRAL PROCESS
Cruz, E.D., Kersten, B.R., Wallis, C.G., Basquez, S.H., Hsu, Y. The
University of Texas M. D. Anderson Cancer Center, Houston, TX.
Patient Access is a vital factor in obtaining new patients and
achieving high levels of Referring Physician (RP) satisfaction in a
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